These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 619476)
41. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. Santen RJ; Worgul TJ; Samojlik E; Interrante A; Boucher AE; Lipton A; Harvey HA; White DS; Smart E; Cox C; Wells SA N Engl J Med; 1981 Sep; 305(10):545-51. PubMed ID: 7019703 [TBL] [Abstract][Full Text] [Related]
42. Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review. Santen RJ Breast Cancer Res Treat; 1981; 1(3):183-202. PubMed ID: 6293627 [TBL] [Abstract][Full Text] [Related]
43. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301 [TBL] [Abstract][Full Text] [Related]
44. Further studies on the relationship of adrenal and gonadal steroids in pubertal development in female rats. Ducharme JR; Morera AM; Laurin P; Collu R; Audi L; Jéquier JC; Saez J Horm Res; 1979; 10(2-3):130-42. PubMed ID: 155640 [TBL] [Abstract][Full Text] [Related]
45. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861). Bruning PF; Bonfrèr JM; Wildiers J; Jassem J; Beex LV; Schornagel J; Nooijen WJ J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1013-9. PubMed ID: 2149501 [TBL] [Abstract][Full Text] [Related]
46. The hormonal activity of the postmenopausal ovary. Vermeulen A J Clin Endocrinol Metab; 1976 Feb; 42(2):247-53. PubMed ID: 177438 [TBL] [Abstract][Full Text] [Related]
47. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Lundgren S; Helle SI; Lonning PE Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328 [TBL] [Abstract][Full Text] [Related]
48. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974 [TBL] [Abstract][Full Text] [Related]
49. Ovarian and adrenal contributions to peripheral steroid levels in postmenopausal women. Maroulis GB; Abraham GE Obstet Gynecol; 1976 Aug; 48(2):150-4. PubMed ID: 133306 [TBL] [Abstract][Full Text] [Related]
50. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Harris AL; Dowsett M; Smith IE; Jeffcoate SL Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746 [TBL] [Abstract][Full Text] [Related]
51. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. Santen RJ; Santner S; Davis B; Veldhuis J; Samojlik E; Ruby E J Clin Endocrinol Metab; 1978 Dec; 47(6):1257-65. PubMed ID: 263348 [No Abstract] [Full Text] [Related]
52. In vivo effects of delta 1-testololactone on peripheral aromatization. Judd HL; Barone RM; Laufer LR; Gambone JC; Monfort SL; Lasley BL Cancer Res; 1982 Aug; 42(8 Suppl):3345s-3348s. PubMed ID: 7083208 [TBL] [Abstract][Full Text] [Related]
53. Low-dose aminoglutethimide in treatment of advanced breast cancer. Stuart-Harris R; Dowsett M; Bozek T; McKinna JA; Gazet JC; Jeffcoate SL; Kurkure A; Carr L; Smith IE Lancet; 1984 Sep; 2(8403):604-7. PubMed ID: 6147642 [TBL] [Abstract][Full Text] [Related]
54. A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Harvey HA; Santen RJ; Osterman J; Samojlik E; White DS; Lipton A Cancer; 1979 Jun; 43(6):2207-14. PubMed ID: 378347 [TBL] [Abstract][Full Text] [Related]
55. The effect of dexamethasone administration at different stages of gestation on maternal plasma steroid concentrations in the baboon (Papio cynocephalus). Castracane VD Hum Reprod; 1998 Aug; 13(8):2282-5. PubMed ID: 9756311 [TBL] [Abstract][Full Text] [Related]
56. Could aminoglutethimide replace adrenalectomy? Harris AL Breast Cancer Res Treat; 1985; 6(3):201-11. PubMed ID: 3912013 [TBL] [Abstract][Full Text] [Related]
57. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. Morris KT; Toth-Fejel S; Schmidt J; Fletcher WS; Pommier RF Surgery; 2001 Dec; 130(6):947-53. PubMed ID: 11742322 [TBL] [Abstract][Full Text] [Related]
58. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. Geisler J; Haynes B; Ekse D; Dowsett M; Lønning PE J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):27-34. PubMed ID: 17350249 [TBL] [Abstract][Full Text] [Related]
59. Estrone and estradiol in patients with cirrhosis of the liver: effects of ACTH and dexamethasone. Kley HK; Krüskemper HL; Keck E J Clin Endocrinol Metab; 1976 Sep; 43(3):557-60. PubMed ID: 182710 [TBL] [Abstract][Full Text] [Related]